CD4 T细胞计数下降与病毒载量受控的HIV感染者启动联合抗逆转录病毒治疗后严重疾病风险的关系(2006-2018)
在ANRS CO4法国医院HIV数据库队列中,选取2006至2018年间启动联合抗逆转录病毒治疗(cART)后病毒抑制且随访≥2年的HIV感染者,评估CD4 T细胞计数下降(连续两次相对差异≥15%)的发生率、相关因素及其与严重疾病或死亡风险的关联。结果显示CD4下降罕见(发生率2.4/1000人年,95%CI 2.1-2.8),与全淋巴细胞减少相关;CD4下降者前6个月严重疾病或死亡风险为无下降者的10.8倍(95%CI 5.1-22.8),6个月后无显著差异。
要点
- CD4下降定义为连续两次相对差异≥15%,在病毒抑制的HIV感染者中罕见,发生率2.4/1000人年。
- CD4下降伴随CD8和总淋巴细胞计数相似下降,提示全淋巴细胞减少。
- CD4下降者前6个月严重疾病或死亡风险为无下降者的10.8倍(95%CI 5.1-22.8),6个月后无显著差异。
核心结论
- 在病毒抑制的HIV感染者中,CD4下降罕见且与全淋巴细胞减少相关,并与前6个月内严重疾病或死亡风险升高相关。
研究设计与样本
- 基于ANRS CO4法国医院HIV数据库队列,选取2006至2018年间启动cART后病毒抑制且随访≥2年的>18岁HIV感染者,共纳入15 714人(75 417人年)。
主要发现
- 181人出现CD4下降,发生率为2.4/1000人年(95%CI 2.1-2.8)。
- CD4下降者中CD8和总淋巴细胞计数也呈相似下降。
- 当前年龄较大和启动治疗时病毒载量较低与CD4下降风险相关。
- CD4下降者前6个月严重疾病或死亡风险为无下降者的10.8倍(发生率比10.8,95%CI 5.1-22.8),6个月后无显著差异。
关键数值与推荐
- CD4下降定义为连续两次相对差异≥15%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A previous study showed an association between CD4 T-cell count decline in people with human immunodeficiency virus infection (PWH) with viral suppression and an increased risk of severe morbid conditions. We aimed to assess the risk of CD4 T-cell count decline (hereafter, CD4 decline), determine associated factors, and evaluate the association of this decline with the risk of severe morbid conditions (cardiovascular disease and cancer) or death. METHODS: From the Agence Nationale de Recherches sur le SIDA et les hépatites virales (ANRS) CO4 French Hospital Database on HIV cohort, we selected PWH >18 years old who had been followed up for ≥2 years after viral suppression following the initiation of combination antiretroviral therapy (cART) between 2006 and 2018. CD4 decline was defined as 2 consecutive relative differences ≥15%. Among participants with such decline, we modeled CD4, CD8, and total lymphocyte counts before and after CD4 decline, using spline regression. The remaining objectives were assessed using Poisson regression, with the association between CD4 decline and the risk of severe morbid conditions or death evaluated during or after 6 months of decline. RESULTS: Among 15 714 participants (75 417 person-years), 181 presented with CD4 decline (incidence rate, 2.4/1000 person-years (95% confidence interval, 2.1-2.8). CD8 and total lymphocyte counts also showed a similar decline. Older current age and lower viral load at treatment initiation were associated with the risk of CD4 decline. The risk of severe morbid conditions or death was 11-fold higher during the first 6 months for participants who presented with CD4 decline versus those who did not (incidence rate ratio, 10.8 [95% confidence interval, 5.1-22.8]), with no significant difference after 6 months. CONCLUSIONS: In PWH with viral suppression, CD4 decline was rare and related to global lymphopenia. It was associated with a higher risk of severe morbid conditions or death during the first 6 months.
引用
- Choufany M, Weiss L, Makinson A, et al. Decrease in CD4 T-Cell Count and Risk of Severe Morbid Conditions in People With Human Immunodeficiency Virus Infection With Controlled Viral Load After Initiating Combination Antiretroviral Therapy Between 2006 and 2018. Clin Infect Dis. 2023. PMID: 36527700. doi:10.1093/cid/ciac939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。